| For: | Xiao R, Jin H, Huang F, Huang B, Wang H, Wang YG. Oncolytic virotherapy for hepatocellular carcinoma: A potent immunotherapeutic landscape. World J Gastrointest Oncol 2024; 16(7): 2867-2876 [PMID: 39072175 DOI: 10.4251/wjgo.v16.i7.2867] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v16/i7/2867.htm |
| Number | Citing Articles |
| 1 |
Huimin Yuan, Ruochen Xu, Senlin Li, Mengzhu Zheng, Qingyi Tong, Ming Xiang, Yonghui Zhang. The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions. MedComm 2025; 6(3) doi: 10.1002/mco2.70121
|
| 2 |
Mariam Ayad Abd, Mohammed Asiri, Shahd Rajab Farhan, Gaurav Sanghvi, Rangaswamy Roopashree, Aditya Kashyap, D. Alex Anand, Rajashree Panigrahi, Yasser Fakri Mustafa, Baneen C. Gabaal. Update on Application of Oncolytic Virus‐Based Combination Therapy in the Treatment of Hepatocellular Carcinoma. Journal of Biochemical and Molecular Toxicology 2025; 39(6) doi: 10.1002/jbt.70327
|
| 3 |
Khulah Sadia, Annalisa Castagna, Silvia Udali, Francesca Ambrosani, Patrizia Pattini, Ruggero Beri, Giuseppe Argentino, Maria Masutti, Sara Moruzzi, Simonetta Friso. Epigenetic Regulation Through Histone Deacetylation: Implications and Therapeutic Potential in Hepatocellular Carcinoma. Cells 2025; 14(17): 1337 doi: 10.3390/cells14171337
|
| 4 |
Yanxi Luo, Zhigao Hu, Guoxiu Du, Wanpeng Xin, Minglong Wang. Novel immune checkpoint inhibitor FilC/PD-1 recombinant vaccinia virus inhibits hepatocellular carcinoma. Frontiers in Medicine 2025; 12 doi: 10.3389/fmed.2025.1622209
|
